Pulmonary Tuberculosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pulmonary Tuberculosis – Drugs In Development, 2024 report and make more profitable business decisions.
Pulmonary tuberculosis (TB) is an infectious respiratory disease caused by Mycobacterium tuberculosis, capable of spreading to other organs. The bacterium is highly contagious, transmitted through air droplets from coughs or sneezes of infected individuals. Initial infection, known as primary TB, may be asymptomatic. When symptoms manifest, they encompass breathing difficulties, chest pain, cough with mucus, blood-tinged sputum, night sweats, fatigue, fever, weight loss, and wheezing. Treatment aims to cure the infection, typically involving a combination of four medications. Administered until lab tests indicate the most effective drugs, this approach addresses active pulmonary TB and underscores the importance of adherence for successful outcomes.
The Pulmonary Tuberculosis drugs in development market research report provide comprehensive information on the therapeutics under development for Pulmonary Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Tuberculosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pulmonary Tuberculosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 25 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pulmonary Tuberculosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pulmonary Tuberculosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pulmonary Tuberculosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alopexx IncArchivel Farma SL
AstraZeneca Plc
Bioversys AG
Bristol-Myers Squibb Co
Changzhou Yinsheng Pharmaceutical Co Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
Genexine Inc
Global Alliance for TB Drug Development
GSK plc
Infectex
Johnson & Johnson
LegoChem Biosciences Inc
Ludwig-Maximilians-University Munich
Nearmedic Plus
Otsuka Pharmaceutical Co Ltd
Qurient Co Ltd
Sequella Inc
Serum Institute of India Pvt Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Thirty Respiratory Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pulmonary Tuberculosis reports